

# David L Rimm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/392654/publications.pdf>

Version: 2024-02-01

266  
papers

27,425  
citations

11908

72  
h-index

8212

153  
g-index

273  
all docs

273  
docs citations

273  
times ranked

33893  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardization of PD-L1 immunohistochemistry. <i>Modern Pathology</i> , 2022, 35, 294-295.	2.9	4
2	Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. <i>Modern Pathology</i> , 2022, 35, 44-51.	2.9	61
3	Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 360-367.	3.2	14
4	Artificial intelligence applied to breast pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 191-209.	1.4	29
5	Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. <i>Cancer Letters</i> , 2022, 526, 346-351.	3.2	10
6	CECR2 drives breast cancer metastasis by promoting NF- $\kappa$ B signaling and macrophage-mediated immune suppression. <i>Science Translational Medicine</i> , 2022, 14, eabf5473.	5.8	51
7	Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. <i>JAMA Oncology</i> , 2022, 8, 607.	3.4	147
8	Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. <i>Npj Breast Cancer</i> , 2022, 8, 29.	2.3	4
9	Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profiling. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 695-698.	0.6	4
10	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2587-2597.	3.2	16
11	Inhibition of renalase drives tumour rejection by promoting T cell activation. <i>European Journal of Cancer</i> , 2022, 165, 81-96.	1.3	2
12	Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies. <i>Statistics in Medicine</i> , 2022, 41, 1361-1375.	0.8	6
13	What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. <i>Cancer Medicine</i> , 2022, 11, 332-339.	1.3	6
14	Abstract P5-13-26: The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study. <i>Cancer Research</i> , 2022, 82, P5-13-26-P5-13-26.	0.4	0
15	Development of an immunohistochemical assay for Siglec-15. <i>Laboratory Investigation</i> , 2022, 102, 771-778.	1.7	8
16	Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. <i>Journal of Thoracic Oncology</i> , 2022, 17, 991-1001.	0.5	14
17	Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. <i>Laboratory Investigation</i> , 2022, 102, 1143-1149.	1.7	5
18	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16

#	ARTICLE	IF	CITATIONS
19	Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. <i>Laboratory Investigation</i> , 2022, 102, 1101-1108.	1.7	53
20	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
21	Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	20
22	Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Oncology</i> , 2022, 40, 594-594.	0.8	0
23	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	2.9	18
24	Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1078-1085.	0.5	5
25	Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 516-516.	0.8	0
26	Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6050-6050.	0.8	1
27	Ki67 as a Companion Diagnostic: Good or Bad News?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3796-3799.	0.8	10
28	Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. <i>EBioMedicine</i> , 2022, 82, 104143.	2.7	12
29	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 131-140.	3.2	93
30	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
31	Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2837-2847.	3.2	17
32	A new tool for technical standardization of the Ki67 immunohistochemical assay. <i>Modern Pathology</i> , 2021, 34, 1261-1270.	2.9	22
33	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 9.	2.3	35
34	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. <i>Scientific Reports</i> , 2021, 11, 2809.	1.6	20
35	Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 479-493.	0.6	28
36	Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer. <i>Cancers</i> , 2021, 13, 1024.	1.7	6

#	ARTICLE	IF	CITATIONS
37	An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy. <i>Modern Pathology</i> , 2021, 34, 1588-1595.	2.9	53
38	Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. , 2021, 9, e002230.		23
39	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1922-1935.	0.6	33
40	STING enhances cell death through regulation of reactive oxygen species and DNA damage. <i>Nature Communications</i> , 2021, 12, 2327.	5.8	78
41	Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. <i>Npj Precision Oncology</i> , 2021, 5, 45.	2.3	11
42	Putting the Microenvironment into the Immunotherapy Companion Diagnostic. <i>Clinical Cancer Research</i> , 2021, 27, 3812-3814.	3.2	2
43	PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. <i>Oral Oncology</i> , 2021, 117, 105292.	0.8	21
44	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. <i>Science</i> , 2021, 372, .	6.0	114
45	Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes. <i>Cancer Research</i> , 2021, 81, 4346-4359.	0.4	22
46	PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1613-1614.	3.0	6
47	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5557-5565.	3.2	26
48	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. , 2021, 9, e002197.		44
49	High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 701492.	1.3	4
50	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6156-6163.	3.2	12
51	Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2139-2143.	0.5	15
52	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021, 13, 4910.	1.7	8
53	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. <i>Clinical Cancer Research</i> , 2021, 27, 1987-1996.	3.2	38
54	Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 150-159.	0.9	9

#	ARTICLE	IF	CITATIONS
55	BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. <i>Oncology</i> , 2021, 99, 580-588.	0.9	5
56	Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. <i>Oncolmmunology</i> , 2021, 10, 1864909.	2.1	18
57	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
58	Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale. <i>Academic Pathology</i> , 2021, 8, 23742895211047985.	0.7	5
59	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 5501.	1.7	10
60	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. <i>Npj Breast Cancer</i> , 2021, 7, 144.	2.3	3
61	52â€...Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI)., 2021, 9, A59-A59.		1
62	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
63	Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a caseâ€“control study. <i>Breast Cancer Research</i> , 2021, 23, 113.	2.2	3
64	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 970-977.	3.2	200
65	â€œInterchangeabilityâ€•of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	2.9	135
66	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. <i>Laboratory Investigation</i> , 2020, 100, 4-15.	1.7	52
67	Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. <i>Clinical Cancer Research</i> , 2020, 26, 1126-1134.	3.2	78
68	Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition. <i>Cancer Research</i> , 2020, 80, 524-535.	0.4	26
69	Benign lymph node microenvironment is associated with response to immunotherapy. <i>Precision Clinical Medicine</i> , 2020, 3, 44-53.	1.3	10
70	How current assay approval policies are leading to unintended imprecision medicine. <i>Lancet Oncology, The</i> , 2020, 21, 1399-1401.	5.1	34
71	Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. , 2020, 8, e001558.		85
72	Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry. <i>BioTechniques</i> , 2020, 69, 460-468.	0.8	34

#	ARTICLE	IF	CITATIONS
73	PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5456-5461.	3.2	60
74	A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study. <i>The Lancet Digital Health</i> , 2020, 2, e594-e606.	5.9	38
75	Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images. <i>Nature Communications</i> , 2020, 11, 6367.	5.8	108
76	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
77	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
78	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
79	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
80	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e275-e291.	1.8	32
81	Advances in quantitative immunohistochemistry and their contribution to breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 509-522.	1.5	13
82	Digital quantitative assessment of PD-L1 using digital spatial profiling. <i>Laboratory Investigation</i> , 2020, 100, 1311-1317.	1.7	25
83	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunooncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
84	Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers. <i>JCO Precision Oncology</i> , 2020, 4, 767-779.	1.5	23
85	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	0.8	673
86	Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. <i>Modern Pathology</i> , 2020, 33, 1746-1752.	2.9	94
87	Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. <i>Clinical Cancer Research</i> , 2020, 26, 4360-4368.	3.2	73
88	Association between low estrogen receptor positive breast cancer and staining performance. <i>Npj Breast Cancer</i> , 2020, 6, 5.	2.3	20
89	Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). <i>Cancer Research</i> , 2020, 80, PD1-01-PD1-01.	0.4	7
90	PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9539-9539.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3166-TPS3166.	0.8	4
92	Abstract P3-08-12: An open source, automated tumor infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer. , 2020, , .		1
93	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Modern Pathology, 2019, 32, 59-69.	2.9	78
94	Artificial intelligence in digital pathology â€” new tools for diagnosis and precision oncology. Nature Reviews Clinical Oncology, 2019, 16, 703-715.	12.5	807
95	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	3.4	431
96	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. , 2019, 7, 194.		47
97	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Nonâ€”Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 2084-2096.	0.5	48
98	Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. Npj Breast Cancer, 2019, 5, 28.	2.3	12
99	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
100	High-Plex Predictive Marker Discovery for Melanoma Immunotherapyâ€”Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research, 2019, 25, 5503-5512.	3.2	117
101	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research, 2019, 21, 72.	2.2	24
102	Immune Checkpoint Inhibitorâ€”Associated Pericarditis. Journal of Thoracic Oncology, 2019, 14, 1102-1108.	0.5	72
103	False-positive pathology: improving reproducibility with the next generation of pathologists. Laboratory Investigation, 2019, 99, 1260-1265.	1.7	11
104	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Nonâ€”Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical Cancer Research, 2019, 25, 4663-4673.	3.2	210
105	Immunotherapy in Nonâ€”Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 2019, 25, 4592-4602.	3.2	447
106	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, 2019, 25, 656-666.	15.2	461
107	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). , 2019, 7, 65.		108
108	Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry. Clinical Cancer Research, 2019, 25, 3054-3062.	3.2	42

#	ARTICLE	IF	CITATIONS
109	An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. Nature Communications, 2019, 10, 5440.	5.8	62
110	A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 263-269.	0.6	28
111	Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. Laboratory Investigation, 2019, 99, 107-117.	1.7	91
112	Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 1526-1534.	3.2	168
113	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 2442-2449.	3.2	106
114	Abstract LB-318: Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE study): Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow. , 2019, , .		5
115	Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. Journal of Clinical Investigation, 2019, 129, 5518-5536.	3.9	92
116	Viagenpumatu cel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.. Journal of Clinical Oncology, 2019, 37, 9109-9109.	0.8	3
117	Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.. Journal of Clinical Oncology, 2019, 37, 9577-9577.	0.8	4
118	Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2019, 37, e14180-e14180.	0.8	0
119	Not Just Digital Pathology, Intelligent Digital Pathology. JAMA Oncology, 2018, 4, 403.	3.4	36
120	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research, 2018, 24, 3282-3291.	3.2	44
121	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. Molecular Cancer Therapeutics, 2018, 17, 1324-1331.	1.9	65
122	An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients. Npj Breast Cancer, 2018, 4, 6.	2.3	7
123	Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity. Scientific Reports, 2018, 8, 4097.	1.6	34
124	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 2018, 52, 16-25.	4.3	303
125	Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing. JAMA Oncology, 2018, 4, 838.	3.4	30
126	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	2.9	278



#	ARTICLE	IF	CITATIONS
127	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	2.3	36
128	CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers. <i>Breast Cancer Research</i> , 2018, 20, 154.	2.2	80
129	Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 86, 278-287.	0.8	32
130	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1884-1896.	0.5	78
131	Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. <i>Npj Breast Cancer</i> , 2018, 4, 32.	2.3	27
132	Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. <i>Laboratory Investigation</i> , 2018, 98, 1438-1448.	1.7	99
133	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)., 2018, 6, 75.		188
134	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260.	3.2	116
135	Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. <i>Laboratory Investigation</i> , 2018, 98, 1076-1083.	1.7	11
136	Abstract 3638: Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. <i>Cancer Research</i> , 2018, 78, 3638-3638.	0.4	7
137	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. <i>JCI Insight</i> , 2018, 3, .	2.3	128
138	Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12015-12015.	0.8	1
139	Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter?. <i>Journal of Clinical Oncology</i> , 2018, 36, 12058-12058.	0.8	3
140	The effect of black cohosh on Ki67 levels in DCIS patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13541-e13541.	0.8	1
141	Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 571-571.	0.8	0
142	PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non-small-cell lung cancer (ES-NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12059-12059.	0.8	0
143	Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12002-12002.	0.8	0
144	Proof of the quantitative potential of immunofluorescence by mass spectrometry. <i>Laboratory Investigation</i> , 2017, 97, 329-334.	1.7	35

#	ARTICLE	IF	CITATIONS
145	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	3.2	117
146	Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. <i>Gynecologic Oncology</i> , 2017, 145, 154-158.	0.6	12
147	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1051.	3.4	658
148	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2017, 23, 5202-5209.	3.2	99
149	Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival. <i>Molecular Cancer Research</i> , 2017, 15, 942-952.	1.5	39
150	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	7.7	507
151	High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence. <i>Laboratory Investigation</i> , 2017, 97, 1521-1526.	1.7	19
152	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-338.	2.4	530
153	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
154	Nuclear IRF-1 expression as a mechanism to assess the capability to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
155	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. <i>Modern Pathology</i> , 2017, 30, 340-349.	2.9	138
156	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. <i>JAMA Oncology</i> , 2017, 3, 256.	3.4	164
157	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 370-378.	3.2	150
158	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. <i>Breast Cancer Research</i> , 2017, 19, 91.	2.2	90
159	Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. , 2017, 5, 81.		33
160	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. <i>Oncotarget</i> , 2017, 8, 11114-11126.	0.8	22
161	Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 519-519.	0.8	4
162	Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9076-9076.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9517-9517.	0.8	2
164	Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.. Journal of Clinical Oncology, 2017, 35, e14611-e14611.	0.8	4
165	ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC. PLoS ONE, 2017, 12, e0181356.	1.1	15
166	[Letter to the Editor] The need for improved education and training in research antibody usage and validation practices. BioTechniques, 2016, 61, 16-18.	0.8	30
167	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
168	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	0.5	329
169	A proposal for validation of antibodies. Nature Methods, 2016, 13, 823-827.	9.0	473
170	EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1901-1911.	0.5	14
171	Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Reports, 2016, 16, 457-471.	2.9	48
172	Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research, 2016, 18, 78.	2.2	75
173	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine, 2016, 8, 334ra53.	5.8	105
174	Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives of Pathology and Laboratory Medicine, 2016, 140, 66-74.	1.2	33
175	Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement. Laboratory Investigation, 2016, 96, 1016-1025.	1.7	9
176	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer, 2016, 115, 303-311.	2.9	27
177	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-“Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 46.	3.4	693
178	Early and multiple origins of metastatic lineages within primary tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2140-2145.	3.3	157
179	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 927-939.	0.4	128
180	Loss of antigenicity with tissue age in breast cancer. Laboratory Investigation, 2016, 96, 264-269.	1.7	34

#	ARTICLE	IF	CITATIONS
181	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 704-713.	3.2	173
182	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428
183	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 374-382.	3.2	38
184	Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11610-11610.	0.8	2
185	Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8566-8566.	0.8	5
186	Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9040-9040.	0.8	2
187	Association between DNA level aberrations and immune cell infiltration in breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3078-3078.	0.8	0
188	High level PHGDH expression in breast is predominantly associated with keratin 5â€positive cell lineage independently of malignancy. <i>Molecular Oncology</i> , 2015, 9, 1636-1654.	2.1	34
189	Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies. <i>Cancer Cell</i> , 2015, 27, 354-369.	7.7	177
190	Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	35
191	Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2591-2600.	3.2	157
192	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 326-332.	1.6	310
193	PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 2138-2147.	3.2	71
194	Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. <i>Human Molecular Genetics</i> , 2015, 24, 2318-2329.	1.4	290
195	Expertise vs Evidence in Assessment of Breast Biopsies. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1109.	3.8	18
196	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	3.2	198
197	Objective Measurement and Clinical Significance of TILs in Nonâ€Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	325
198	Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. <i>Laboratory Investigation</i> , 2015, 95, 385-396.	1.7	71

#	ARTICLE	IF	CITATIONS
199	Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. <i>Laboratory Investigation</i> , 2015, 95, 334-341.	1.7	52
200	Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3067-3067.	0.8	3
201	The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15504-e15504.	0.8	4
202	Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1087-1087.	0.8	1
203	Correlation of miR200a expression with survival in patients with small, lymph node negative head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17062-e17062.	0.8	0
204	Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>PLoS ONE</i> , 2014, 9, e94273.	1.1	41
205	A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. <i>Laboratory Investigation</i> , 2014, 94, 467-474.	1.7	48
206	Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. <i>Clinical Cancer Research</i> , 2014, 20, 3023-3032.	3.2	34
207	Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. <i>Proteome Science</i> , 2014, 12, 40.	0.7	57
208	Next-gen immunohistochemistry. <i>Nature Methods</i> , 2014, 11, 381-383.	9.0	39
209	Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. <i>Laboratory Investigation</i> , 2014, 94, 98-106.	1.7	83
210	Programmed death ligand-1 expression in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2014, 94, 107-116.	1.7	697
211	ER $\alpha$ splice variant expression in four large cohorts of human breast cancer patient tumors. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 657-667.	1.1	39
212	Unvalidated antibodies and misleading results. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 457-458.	1.1	29
213	Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. <i>BMC Cancer</i> , 2014, 14, 326.	1.1	21
214	Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5995-6005.	3.2	149
215	<i>In Situ</i> Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas. <i>Clinical Cancer Research</i> , 2014, 20, 2773-2782.	3.2	403
216	Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8064-8064.	0.8	12

#	ARTICLE	IF	CITATIONS
217	In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. PLoS ONE, 2014, 9, e99131.	1.1	21
218	Clinical significance of TILs subtypes in non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, 8082-8082.	0.8	0
219	Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2014, 32, 1027-1027.	0.8	0
220	Tissue microarrays: leaping the gap between research and clinical adoption. Personalized Medicine, 2013, 10, 441-451.	0.8	12
221	A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant Cells. Archives of Pathology and Laboratory Medicine, 2013, 137, 1545-1549.	1.2	85
222	Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 6012-6012.	0.8	4
223	Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA), paclitaxel (P), and cetuximab (C) induction and chemoradiation (CRT) in patients (pts) with resectable stage III/IVa,b head and neck squamous cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303.. Journal of Clinical Oncology, 2013, 31, 6081-6081.	0.8	0
224	Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2013, 31, 1085-1085.	0.8	0
225	A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ.. Journal of Clinical Oncology, 2013, 31, TPS1609-TPS1609.	0.8	0
226	Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues. Journal of the National Cancer Institute, 2012, 104, 1815-1824.	3.0	103
227	Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. BioTechniques, 2012, 52, 235-245.	0.8	57
228	Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.. Journal of Clinical Oncology, 2012, 30, 517-517.	0.8	5
229	Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen. PLoS ONE, 2012, 7, e36559.	1.1	57
230	Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2012, 30, 5576-5576.	0.8	1
231	Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis.. Journal of Clinical Oncology, 2012, 30, e21106-e21106.	0.8	0
232	Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?. Journal of Clinical Oncology, 2012, 30, 1121-1121.	0.8	0
233	In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.. Journal of Clinical Oncology, 2012, 30, 573-573.	0.8	0
234	Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Laboratory Investigation, 2011, 91, 1253-1261.	1.7	55

#	ARTICLE	IF	CITATIONS
235	Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells. <i>Journal of Clinical Oncology</i> , 2011, 29, 2978-2984.	0.8	71
236	Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues. <i>Journal of Clinical Oncology</i> , 2011, 29, 2282-2290.	0.8	25
237	C-Path: A Watson-Like Visit to the Pathology Lab. <i>Science Translational Medicine</i> , 2011, 3, 108fs8.	5.8	15
238	Reply to A. Italiano. <i>Journal of Clinical Oncology</i> , 2011, 29, 4718-4719.	0.8	11
239	Antibody validation. <i>BioTechniques</i> , 2010, 48, 197-209.	0.8	548
240	Analytic Variability in Immunohistochemistry Biomarker Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 982-991.	1.1	83
241	Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. <i>Breast Cancer Research</i> , 2010, 12, 113.	2.2	24
242	A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers. <i>Journal of Clinical Oncology</i> , 2008, 26, 5630-5637.	0.8	235
243	Bimodal Population or Pathologist Artifact?. <i>Journal of Clinical Oncology</i> , 2007, 25, 2487-2488.	0.8	23
244	What brown cannot do for you. <i>Nature Biotechnology</i> , 2006, 24, 914-916.	9.4	126
245	Immunohistochemistry and Quantitative Analysis of Protein Expression. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1026-1030.	1.2	155
246	Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1808-1815.	3.0	252
247	X-Tile. <i>Clinical Cancer Research</i> , 2004, 10, 7252-7259.	3.2	2,925
248	Automated subcellular localization and quantification of protein expression in tissue microarrays. <i>Nature Medicine</i> , 2002, 8, 1323-1328.	15.2	705
249	Diagnosis of ?ASCUS? in women over age 50 is less likely to be associated with dysplasia. <i>Diagnostic Cytopathology</i> , 2001, 24, 132-136.	0.5	39
250	Novel inactivating mutations of transforming growth factor-? type I receptor gene in head-and-neck cancer metastases. <i>International Journal of Cancer</i> , 2001, 93, 653-661.	2.3	78
251	A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. , 2000, 88, 108-113.		58
252	Molecular biology in cytopathology. , 2000, 90, 1-9.		12

#	ARTICLE	IF	CITATIONS
253	E-cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens. , 2000, 22, 263-267.		6
254	Author reply. Cancer, 2000, 89, 218-219.	2.0	1
255	Validation of Tissue Microarray Technology in Breast Carcinoma. Laboratory Investigation, 2000, 80, 1943-1949.	1.7	714
256	A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer, 2000, 88, 108-113.	2.0	1
257	Expression of c-met is a strong independent prognostic factor in breast carcinoma. , 1998, 82, 1513-1520.		175
258	Polymerase chain reaction-based detection of clonality as a non-morphologic diagnostic tool for fine-needle aspiration of the breast. , 1998, 84, 262-267.		7
259	A Mutation in $\beta$ -Catenin Disrupts Adhesion in Clone A Cells Without Perturbing its Actin and $\beta$ -Catenin Binding Activity. Cell Adhesion and Communication, 1998, 5, 283-296.	1.7	15
260	Degree of dysplasia following diagnosis of atypical squamous cells of undetermined significance is influenced by patient history and type of follow-up. Diagnostic Cytopathology, 1997, 17, 14-19.	0.5	15
261	Comparison of the costs of fine-needle aspiration and open surgical biopsy as methods for obtaining a pathologic diagnosis. , 1997, 81, 51-56.		77
262	The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids. Cancer, 1997, 81, 293-298.	2.0	45
263	Atypical reparative change on cervical/vaginal smears may be associated with dysplasia. , 1996, 14, 374-379.		11
264	Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the $\alpha$ 5 $\beta$ 1 integrin. Nature, 1994, 372, 190-193.	13.7	1,120
265	Characterization of alpha-actinin from Acanthamoeba. Cytoskeleton, 1986, 6, 649-661.	4.4	17
266	In situ techniques for protein analysis in tumor tissue. , 0, , 76-84.		0